Phase 2 clinical trial

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.

The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...

Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.

Cure8 could only read part of this source from ground.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...

This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...

Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...

A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Timing of mesalamine might change how much drug reaches the colon, gut inflammation markers, and the microbiome — which could affect symptom control or monitoring for people with UC. This trial tests that idea in people...

A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...

Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...

This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...

Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Stricture, and Research and clinical trials. The original article is from firstwordpharma.com.

Fatigue greatly affects quality of life for people with IBD even in remission; if effective and scalable, a mobile CBT program could offer accessible symptom support. The trial will also examine engagement factors...

Self-management programs that teach cognitive behavioral strategies, symptom tracking, relaxation, sleep and diet skills could help people with IBD manage symptoms and day-to-day quality of life without relying solely on...

New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...

This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...

Real-world registries can show how a drug performs outside clinical trials and how patients feel over time; this study aimed to track symptoms for people starting mirikizumab for ulcerative colitis.

Perianal fistulising Crohn's disease is hard to treat and often fails anti-TNF drugs. This study will provide real-world data on whether upadacitinib can be effective and safe for patients with refractory perianal...

FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...

FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.

Fibrotic strictures are a major cause of symptoms and surgery in Crohn’s disease; an oral anti‑fibrotic drug could offer a non‑surgical treatment option if trials show benefit and safety. This study tests RXC008...

A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...

This Phase 2 trial is testing a new oral drug (ATH-063) for adults with moderately to severely active ulcerative colitis who have not responded to prior biologic or advanced therapies, a group that often needs additional...

This highlights a new, biologically distinct drug target (IL‑7Rα) in ulcerative colitis that may help patients who do not respond to existing biologics, and it summarizes early clinical evidence for lusvertikimab while...

Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...

The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.

Noninvasive detection of intestinal fibrosis activity could help identify patients at risk of progressive scarring and surgery, and enable development or targeting of anti-fibrotic treatments for Crohn's disease.

Older adults with IBD face tradeoffs between effectiveness and safety of advanced therapies; this study aims to identify immune‑aging and frailty markers that might predict who is more likely to benefit without serious...

Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.

Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.

Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Research and clinical trials.

A new Phase 2 trial is testing afimkibart (RO7790121) for moderate-to-severe Crohn's disease; people with Crohn's disease who have failed prior treatments may be especially interested in emerging therapies.

Enteral nutrition (Modulen IBD) is being evaluated as a non-drug induction and maintenance strategy in children with Crohn’s disease; patients and caregivers may be interested because EEN can affect remission, nutrition,...

This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...

Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...

Fatigue is a common, disabling symptom in people with quiescent IBD and currently lacks approved pharmacological treatments. This trial tests whether modafinil can safely reduce fatigue and improve daily functioning for...

This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...

If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.

This trial tests a new oral drug, SAR441566, as a potential treatment for moderate-to-severe ulcerative colitis. Results could affect future treatment options if the drug is effective and safe.

This trial tests a new oral drug for moderate to severe ulcerative colitis with a short (12-week) primary endpoint; people with active UC may be interested in emerging treatment options and clinical trial opportunities.

This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...

The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...

This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...